Evidence map›Paper›PMID 30967900›Full record

ArticleFrontiers in genetics2019

A Combined

Gabrielle Wheway, Liliya Nazlamova, Nervine Meshad, Samantha Hunt, Nicola Jackson, Amanda Churchill

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Genetic dissection of non-syndromic retinitis pigmentosa.Indian journal of ophthalmology · 2022
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Gabrielle WhewayCentre for Research in Biosciences, University of the West of England, Bristol, United Kingdom.
Liliya NazlamovaCentre for Research in Biosciences, University of the West of England, Bristol, United Kingdom.
Nervine MeshadBristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.
Samantha HuntBristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.
Nicola JacksonClinical Genetics Service, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.
Amanda ChurchillBristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.
Bristol Eye Hospital · GBUniversity Hospitals Bristol NHS Foundation Trust · GBUniversity of the West of England · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

At least six different proteins of the spliceosome, including PRPF3, PRPF4, PRPF6, PRPF8, PRPF31, and SNRNP200, are mutated in autosomal dominant retinitis pigmentosa (adRP). These proteins have recently been shown to localize to the base of the connecting cilium of the retinal photoreceptor cells, elucidating this form of RP as a retinal ciliopathy. In the case of loss-of-function variants in these genes, pathogenicity can easily be ascribed. In the case of missense variants, this is more challenging. Furthermore, the exact molecular mechanism of disease in this form of RP remains poorly understood. In this paper we take advantage of the recently published cryo EM-resolved structure of the entire human spliceosome, to predict the effect of a novel missense variant in one component of the spliceosome; PRPF31, found in a patient attending the genetics eye clinic at Bristol Eye Hospital. Monoallelic variants in

Indexed as

genetic diseasemissensemodelingpathogenicitypre-mRNA splicing factorretinal ciliopathyretinitis pigmentosa

Identifiers

PMID30967900
PMCPMC6438860
OpenAlexW2950686858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.